ARTICLE | Company News
Via Allergan hair loss deal, Exicure builds balance sheet to advance oncology, neurology pipeline
November 14, 2019 3:00 PM UTC
Updated on Nov 14, 2019 at 9:43 PM UTC
A collaboration deal giving Allergan options to obtain rights to Exicure's hair loss programs will provide the biotech with non-dilutive cash to further advance a pipeline of spherical nucleic acid (SNA) therapeutics for oncology, neurology and other therapeutic areas.
Exicure Inc. (NASDAQ:XCUR) is receiving $25 million up front in the deal, which includes $97.5 million in development and regulatory milestones for each of two programs, as well as $265 million in commercial milestones for each. The potential payouts add up to $725 million in milestones, plus royalties up to the mid-teens...